BIG PHARMA

Pipeline Strategy for Preclinical and Early Clinical Assets

Thursday, November 19th, 2020

10:00 – 11:00am EST

Join Our Live Panel

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This panel brings togerther speakers from various big pharma companies discussing topics such as:

  • How big pharma sources assets
  • The evaluation and investment process
  • Key factors of interest
  • How early-stage big pharma is willing to look

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

Panelists:

Request a Meeting

Ravi Ramadas, Director, Immunology External Innovation, Global BD&L, Sanofi

Immunologist with broad experience in pharma, biotech and academia. Discovery biology, drug discovery, group, program and portfolio leadership experience in immunology and immuno-oncology R&D from target ID to early clinical development. Extensive Search & Evaluation experience in Pharma and Biotech as part of BD&L teams. Keen eye for emerging and breakthrough areas in the life sciences sector. 

Request a Meeting

Tim Luker, Senior Director, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Co

Tim Luker is currently VP External Innovation at Eli Lilly. He leads Lilly’s external advancing innovation process within Global Corporate Business Development. This role supports Lilly’s external VC funds targeting transformational early stage research across 4 therapy areas and runs due diligence and search and evaluation initiatives.Tim is an experienced drug hunter with 17 years’ experience (>60 patents and publications). Prior to Lilly he worked at Shire, Polleo Pharma (founder) and AstraZeneca.Tim has a PhD in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam and is a Prince2 qualified project manager.

Request a Meeting

Lisa Mendoza, Director, External Research & Alliances, Open Innovation – Digital Technologies, Bayer

Dr. Mendoza has served as a Director for Bayer’s Global External Innovation & Alliances, a team of scientists working to establish partnerships with academic and biotech researchers focused on novel therapeutics, drug discovery platforms and technologies in areas of cardiology, hematology, oncology, women’s health and ophthalmology. As part of Global External Innovation & Alliances at Bayer, Mendoza supported the company’s incubator space adjacent to Bayer’s West Coast Innovation Center, the CoLaborator, to support start-up life sciences companies aligned with Bayer’s interests. Dr. Mendoza earned her Ph.D. at UC San Diego in Biology and after her postdoctoral studies in Immunology at UC Berkeley joined Berlex Biosciences working in the Immunology Department on both small molecule and biologic discovery projects before joining Bayer.

Request a Meeting

Ronald Dorenbos, Founder and Managing Director, BioFrontline Ltd.

As former Head of Innovation Management and Scouting and member of Takeda’s Digital Strategy team Ronald helped Takeda with its technology and innovation strategy. Earlier, at the Life Science division of PA Consulting, Ronald led projects for some of the world’s top 10 pharmaceutical companies around strategy, commercialization and digital health. As founder of BioFrontline he provides management, strategy and commercial advice to life sciences companies in the US, Europe and Asia. After obtaining MAs in Biotechnology and Molecular Biology and a PhD in Pharmaceutical Biology in the Netherlands Ronald led research projects on Parkinson’s disease, Schizophrenia and the genetics of aggressive behavior, before making the transition to industry. As a consultant Ronald got involved in projects related to artificial intelligence and he has been following the field for over 10 years. He is frequently invited to deliver presentations and keynotes related to AI in Pharma and Healthcare and has presented at national and international events. Ronald founded the LinkedIn groups ‘AI – Artificial Intelligence’, ‘Small Molecules’, ‘Boston Biotech’ and ‘Golden Triangle Biotech’ that serve over 10,000 members.